Clinical Trial Update: Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) [Phase 3]

View source ↗

Summary

Phase 3 FLEX trial evaluating first-line cisplatin/vinorelbine with or without cetuximab in advanced non-small cell lung cancer; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• ERBITUX (cetuximab)
• Navelbine (vinorelbine)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Non Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: COMPLETED | Results posted: 2011-10-04